Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.
Cizzle Biotechnology Holdings PLC has entered a strategic licensing and partnership agreement with Cizzle Bio Inc for the North American market, securing a $300,000 upfront royalty payment. This exclusive deal aims to launch Cizzle’s CIZ1B biomarker lung cancer blood test in the USA and Canada, fostering significant revenue streams and equity participation. With support from a highly experienced management team and partnerships with leading cancer centers, the company is poised for a full market launch in 2025.
For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.
